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Background
Drug reaction with eosinophilia and systemic symptoms
(DRESS) is among the most severe forms of drug hyper-
sensitivity [1]. Antiepileptics are by far the most com-
monly reported causative drugs [2]. Antibiotics have
seldom been reported apart from minocycline [3].
Case
We describe a 55 years old female who developed DRESS
with acute liver and kidney failure after being treated
with ceftazidime and vancomycine. She was successfully
treated with corticosteroids although while tapering pre-
dnisone she experienced a recurrence of the skin erup-
tion without any systemic symptoms. She was taken off
corticosteroids after 9 months of treatment.
In vitro tests
Fourteen months after the drug reaction, in vitro tests to
identify the causal agent were performed. The lymphocyte
transformation test (LTT) showed a marked proliferation
to ceftazidime (stimulation index (SI): 17 at 100mcg/mL).
CD25 was upregulated on CD4+ (induced expression:
17%) and CD8+ (induced expression: 8%) T cells as shown
by flow cytometry when cultured with ceftazidime
50 mcg/mL. IFN-g was markedly elevated in the superna-
tant of peripheral blood mononuclear cells (PBMC) cul-
tured with ceftazidime 50 mcg/mL when compared to the
control media (946 vs 13 pg/mL). Vancomycin did not
induce a significant response when compared to the con-
trol media in the flow cytometry and the IFN-g assays.
Conclusions
This is the first report of ceftazidime-induced DRESS to
be subsequently proven by allergy tests. This case
illustrates the importance of considering every suscepti-
ble drug as the potential etiologic agent. We also show
the usefulness of in vitro tests in their identification.
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